Question · asked by 1 review
Pregabalin vs placebo: Withdrawals due to adverse events
- Population
- children and adolescents with chronic non‐cancer pain
- Intervention
- Pregabalin
- Comparison
- placebo
- Outcome
- Withdrawals due to adverse events
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pregabalin vs placebo Withdrawals due to adverse events · children and adolescents (birth to 17 years of age) with chronic non‐cancer pain Antiepileptic drugs for chronic non‐cancer pain in children and adolescents (2017) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 107 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Pregabalin vs placebo · people with drug‐resistant focal epilepsy · 1 review
- Pregabalin vs active comparators · people with drug‐resistant focal epilepsy · 1 review
- Pregabalin vs placebo · adults with fibromyalgia · 1 review
- Pregabalin vs placebo at end of treatment · patients with fibromyalgia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.